Navigation Links
Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
Date:6/4/2008

o antibodies. Characteristics of aptamers include high specificity and affinity, and the ability to target protein-protein interactions.

NU172 is an aptamer designed to directly inhibit thrombin's ability to stimulate blood clot formation in the setting of medical procedures where human blood is exposed to foreign materials. Specifically, NU172 is being studied for use as a potential short-acting anticoagulant during procedures such as coronary artery bypass graft surgery and percutaneous interventions. Data from the Phase 1 trial and preclinical studies suggest that NU172 has the potential for predictable anticoagulant effects, rapid onset and offset of action, and avoidance of thrombocytopenia.

About Nuvelo and Archemix's Joint Collaborative Effort

In August 2006, Nuvelo expanded its collaboration with Archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, Archemix is responsible for discovery of short-acting aptamers for use in medical procedures, and Nuvelo leads development and worldwide commercialization of these aptamers.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
2. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
3. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
4. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
5. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
6. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
7. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
8. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
9. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
10. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
11. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... LONDRES, August 29, 2015 ... para los sistemas de imagen por Ultrasonidos   ... tiempos de examen rápidos y un flujo de trabajo ... diagnóstica en el proceso de detección de Cardiopatías   ... ha anunciado hoy el lanzamiento europeo de HeartModel ...
(Date:8/28/2015)... 28, 2015 According to a ... (Breast, Lung, Prostate) Type (Protein & Genetic Biomarkers) Profiling ... Prognostic) & Geography - Global Forecast to 2020", published ... reach around 17,689.0 Million USD by 2020 at a ... to 2020. Browse 191 Tables and ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ... Report on China,s Tobramycin Market, 2010-2019" report to ... whose eye drop and ointment are the most common ... inflammation caused by eye infection. Currently, dozens of enterprises ... produce tobramycin, among which the Top 5 are s.a. ...
Breaking Medicine Technology:Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Tobramycin Market, 2015-2019 2
... UNION CITY, Calif. , Jan. 28 ABAXIS, Inc. (Nasdaq: ... today reported financial results for the fiscal quarter ended December 31, ... $31.0 million , up 15% over last year,s comparable quarter. ... over last year,s comparable quarter. Veterinary market sales of $23.9 ...
... , GLEN BURNIE, Md. , Jan. 28 ... (OSA) and of those, only 5 to 10 percent have been ... and untreated OSA; however, once detected, OSA can be readily and ... stay in a sleep lab, with a technician directly monitoring a ...
Cached Medicine Technology:Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 2Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 3Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 4Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 5Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 6Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 7Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 8Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 9Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 10Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 11Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 12NovaSom(R) Diagnostic System Can Assist in Raising Diagnosis Rate for Potentially Lethal Condition 2NovaSom(R) Diagnostic System Can Assist in Raising Diagnosis Rate for Potentially Lethal Condition 3
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare ... for the treatment of prostate cancer, has announced the roll-out of its newest ... treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, ... Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your ... lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 ...
(Date:8/29/2015)... ... , ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, ... the chiropractic field in the military. All too often VA hospitals treat patients with ... available to the VA program over a decade ago, the reality is that only ...
(Date:8/29/2015)... Calgary, AB (PRWEB) , ... August 29, 2015 ... ... congestive heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are ... conditions such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia ...
(Date:8/28/2015)... Tempe, AZ (PRWEB) , ... August 29, 2015 , ... ... to reinvent higher learning and the student experience as part of the EDUCAUSE - ... Melinda Gates Foundation . , This is the third Breakthrough Models Incubator ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... PRINCETON, N.J., March 9 NJHA Corporate Services ... Morganville, N.J., to offer training and consulting services ... the healthcare environment. The deal comes on the ... Facilities Act, which directs healthcare facilities to establish ...
... Pa., March 9 Genaera Corporation (Nasdaq: ... Rule 4350(b)(1)(B), that the audit report included in the ... the fiscal year ended December 31, 2008 contained an ... firm, KPMG LLP, which included a "going concern" explanatory ...
... action, which is expected to kick-start efforts to unlock ... Separating science from politics with his signature, President Barack ... research on Monday. , During a late morning press ... limits on such research that were first imposed by ...
... Name Youth as ,First Responders, , in the ... order to address the growing childhood obesity epidemic, ... supporting youth-led projects that focus on healthy lifestyles ... two national partners also published an educational guide ...
... against the disease, study finds , , MONDAY, March 9 (HealthDay ... that puts them at higher risk of breast cancer tend ... Several type of risk management strategies are available to women ... is known to elevate a woman,s risk of breast cancer. ...
... Medicare Advantage Special Needs Plans, Tips for Healthy ... A series of free seminars designed to help ... a healthy lifestyle and learn about Medicare Advantage ... will be offered during March at various locations ...
Cached Medicine News:Health News:NJHA, McNamara and Associates Inc. Team Up to Provide Strategies for Controlling Workplace Violence 2Health News:Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 2Health News:Obama Lifts Ban on Stem Cell Research 2Health News:Obama Lifts Ban on Stem Cell Research 3Health News:Obama Lifts Ban on Stem Cell Research 4Health News:'HEROES' Grants, Education Guide Support Youth Leaders Addressing Childhood Obesity Epidemic 2Health News:'HEROES' Grants, Education Guide Support Youth Leaders Addressing Childhood Obesity Epidemic 3Health News:Women With Breast Cancer Gene Favor Preventive Mastectomy 2Health News:Free Seminars Offered to South Carolina Seniors with Diabetes and Other Chronic Illnesses 2
Simplicity and multi-directional retraction for a broad range of abdominal procedures...
... genuine BOOKWALTER™ Retractor System represents the ... design available. Its wide array of ... with a versatile system for multi-directional ... BOOKWALTER™ Kits are available for specific ...
Rainbow technology combines the latest in system theory, adaptive signal processing and a revolutionary sensor that employs eight wavelengths of light to collect and analyze an extraordinarily rich s...
... Another breakthrough in real-time PCR analysis ... mutation analysis. ,The LightCycler 480 System ... and will meet the needs of ... in genomics research including array validation, ...
Medicine Products: